Clinical Trial Update: A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 dose-ranging, evaluator-blinded trial evaluating the safety of topical IDP-118 in plaque psoriasis; status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• IDP-118 (IDP-118)

Snippet

Sponsor: Dow Pharmaceutical Sciences | Conditions: Plaque Psoriasis | Phase 1, Phase 2 | Status: UNKNOWN